SGRF gene-modified mouse

Details SGRF gene-modified mouse SGRF gene-modified mouse

2009-07-08

2010-11-09

Falk, Anne-Marie (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Method of using a transgenic nonhuman animal in an in vivo...

C800S018000

Reexamination Certificate

active

07829757

ABSTRACT:
A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells in which one SGRF gene alleles was inactivated. By crossing these mice with each other, the present inventors succeeded in producing mice in which both SGRF gene alleles were inactivated. These genetically modified animals can be used to predict the side effects of drugs such as SGRF antagonists.

REFERENCES:
patent: 6610285 (2003-08-01), Hirata
patent: 2004/0258686 (2004-12-01), Chirica et al.
patent: 1 072 610 (2001-01-01), None
patent: WO 99/54357 (1999-10-01), None
patent: WO 02/33054 (2002-04-01), None
Brombacher et al., “IL-12 is dispensable for innate and adaptive immunity against low doses of Listeria monocytogenes,” International Immunology 11(3):325-332 (1999).
Capecchi, “The new mouse genetics: Altering the genome by gene targeting,” Trends in Genetics, 5(3):70-76 (1989).
Cytokines / Zousyoku Inshi, Jikken Igaku Bessatsu Bio Science Yougo Library, 1998; Revised edition: 86-7. (English translation attached).
Decken et al. “Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans,” Infection and Immunity 66(10):4994-5000 (1998).
Lariviere et al., “Transgenic Studies of Pain and Analgesia: Mutation or Background Genotype?” J. Pharm. And Exp. Therap. 297:467-473 (2001).
Leonard et al., “Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against Interleukin 12,” J. Exp. Med. 181(1):381-386 (1995).
Magram et al., “IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine Responses,” Immunity 4(5):471-481 (1996).
Moreadith et al., “Gene targeting in embryonic stem cells: the new physiology and metabolism,” J. Mol. Med. 75:208-216 (1997).
Mullins et al., “Perspectives Series: Molecular Medicine in Genetically Engineered Animals,” J. Clin. Invest. 98:S37-S40 (1996).
Oppmann et al., “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12,” Immunity 13(5):715-725 (2000).
Seamark, “Progress and Emerging Problems in Livestock Transgenesis: a Summary Perspective,” Reprod. Fertil. Dev. 6:653-657 (1994).
Segal et al., “An Interleukin (IL)-10/IL-12 Immunoregulatory Circuit Controls Susceptibility to Autoimmune Disease,” The Journal of Experimental Medicine 187(4):537-546 (1998).
Sigmund, “Viewpoint: Are Studies in Genetically Altered Mice Out of Control?” Arterioscler. Thromb. Vasc. Biol., pp. 1425-1429 (2000).
Takai et al., “FcR gamma chain deletion results in pleiotrophic effector cell defects,” Cell 76(3):519-529 (1994).
Wakeham et al., “Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection byMycobacterium bovisBacilli Calmete-Guerin in IL-12-deficient mice,” The Journal of Immunology 160:6101-6111 (1998).
Wiekowski et al. “Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death,” The Journal of Immunology 166:7563-7570 (2001).
Fish & Richardson P.C., Preliminary Amendment, in U.S. Appl. No. 10/493,526, filed Apr. 22, 2004 (7 pages).
Restriction Requirement, in U.S. Appl. No. 10/493,526, mailed Nov. 3, 2005 (6 pages).
Fish & Richardson P.C., Response to Restriction Requirement, in U.S. Serial No. 10/493,526, mailed Nov. 3, 2005, filed Apr. 28, 2006 (6 pages).
Office Action, in U.S. Appl. No. 10/493,526, mailed May 22, 2006, (12 pages).
Fish & Richardson P.C., Response to Office Action, in U.S. Appl. No. 10/493,526, mailed May 22, 2006, filed Nov. 21, 2006 (7 pages).
Office Action, in U.S. Appl. No. 10/493,526, mailed Feb. 26, 2007 (9 pages).
Fish & Richardson P.C., Response to Office Action, in U.S. Appl. No. 10/493,526, mailed Feb. 26, 2007, filed Aug. 27, 2007 (8 pages).
Office Action, in U.S. Appl. No. 10/493,526, mailed Nov. 16, 2007 (15 pages).
Fish & Richardson P.C., Response to Office Action, in U.S. Appl. No. 10/493,526, mailed Nov. 16, 2007, filed Mar. 14, 2008 (8 pages).
Office Action, in U.S. Appl. No. 10/493,526, mailed Jul. 3, 2008 (10 pages).
Fish & Richardson P.C., Request for Continued Examination and Amendment in Reply to Final Office Action, in U.S. Appl. No. 10/493,526, filed Jan. 2, 2009 (8 pages).
Notice of Allowance, in U.S. Appl. No. 10/493,526, mailed Apr. 9, 2009 (8 pages).

Affiliated with

Also associated with

Rating

SGRF gene-modified mouse does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SGRF gene-modified mouse, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SGRF gene-modified mouse will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4197917